Safety and Efficacy of Inhaled Human Insulin (Exubera) During Discontinuation and Readministration of Therapy in Adults with Type 2 Diabetes: A 3-Year Randomized Controlled Trial
The DOI matches its Crossref record.
Abstract
OBJECTIVE: This study assessed pulmonary safety following discontinuation and readministration of inhaled human insulin {Exubera [EXU] [Pfizer Inc., New York, NY] (insulin human [recombinant DNA origin]) inhalation powder} in adults with type 2 diabetes (T2DM). METHODS: Patients were randomized to receive EXU (n = 316) or subcutaneous (SC) insulin (n = 311) for 2 years (comparative phase), followed by 6 months of SC insulin (washout phase) and 6 months of original therapy (readministration). Highly standardized lung function tests were performed throughout all phases. RESULTS: Small, nonprogressive treatment group differences were observed to occur early during the comparative phase for parameters such as change from baseline for forced expiratory volume in 1 s (FEV(1)) and carbon monoxide diffusing capacity (DL(CO)). These differences resolved during washout and recurred to the same small magnitude during readministration. Both treatment groups maintained similar glycemic control and hypoglycemic event rates. In the EXU group, insulin antibody (IAb) levels reached a plateau at 9 months, declined to near baseline levels during washout, and increased during readministration to levels observed in the comparative phase. CONCLUSIONS: FEV(1) and DL(CO) changes observed during discontinuation and readministration of EXU therapy were consistent with a reversible, nonprogressive, and nonstructural pathologic effect on lung function in adults with T2DM. EXU readministration was not associated with an augmented IAb response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Treatments for women with gestational diabetes mellitus: an overview of Cochrane systematic reviews
Martis, R., Crowther, C. A., Shepherd, E., Alsweiler, J., Downie, M. R., & Brown, J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012327.pub2 · Cited by 159
Results of a 24-week trial of technosphere insulin versus insulin aspart in type 2 diabetes
Hoogwerf, B. J., Pantalone, K. M., Basina, M., Jones, M. C., Grant, M., & Kendall, D. M. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2020.11.002 · Cited by 22
Metadata
- Authors
- Rosenstock, J., Cefalu, W. T., Hollander, P. A., Klioze, S. S., Reis, J., & Duggan, W. T.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2009-11
- Volume
- 11
- Issue
- 11
- Pages
- 697-705
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2072429020
- Cited by
- 45
- References
- 0
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Efficacy of Inhaled Human Insulin (Exubera) During Discontinuation and Readministration of Therapy in Adults with Type 2 Diabetes: A 3-Year Randomized Controlled Trial. https://app.cochat.ai/papers/10.1089/dia.2009.0062
- The paper
- Rosenstock, J., Cefalu, W. T., Hollander, P. A., Klioze, S. S., Reis, J., & Duggan, W. T. (2009). Safety and Efficacy of Inhaled Human Insulin (Exubera) During Discontinuation and Readministration of Therapy in Adults with Type 2 Diabetes: A 3-Year Randomized Controlled Trial. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2009.0062
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.